Details for Patent: 9,447,104

Which drugs does patent 9,447,104 protect, and when does it expire?

Patent 9,447,104 protects VITRAKVI and is included in two NDAs.

This patent has one hundred and ten patent family members in thirty-eight countries.

Summary for Patent: 9,447,104

Title:	Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Abstract:	Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.
Inventor(s):	Haas; Julia (Boulder, CO), Andrews; Steven W. (Boulder, CO), Jiang; Yutong (Boulder, CO), Zhang; Gan (Niwot, CO)
Assignee:	Array BioPharma, Inc. (Boulder, CO)
Application Number:	14/490,460
Patent Claim Types: see list of patent claims	Use; Delivery;

Drugs Protected by US Patent 9,447,104

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Hlthcare	VITRAKVI	larotrectinib sulfate	CAPSULE;ORAL	210861-001	Nov 26, 2018		RX	Yes	No						METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
Bayer Hlthcare	VITRAKVI	larotrectinib sulfate	CAPSULE;ORAL	210861-002	Nov 26, 2018		RX	Yes	Yes						METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
Bayer Healthcare	VITRAKVI	larotrectinib sulfate	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes						METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION

International Family Members for US Patent 9,447,104

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	074052
Argentina	112833
Australia	2009308465